U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Emicizumab

Last Revision: November 15, 2023.

Estimated reading time: 1 minute

CASRN: 1610943-06-0

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of emicizumab during breastfeeding. Because emicizumab is a large protein molecule with a molecular weight of 145,600, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
2.
Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
3.
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66. [PubMed: 36931808]

Substance Identification

Substance Name

Emicizumab

CAS Registry Number

1610943-06-0

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Bispecific

Antibodies, Monoclonal, Humanized

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500955PMID: 30000014

Views

Related information

Similar articles in PubMed

  • Review Risankizumab.[Drugs and Lactation Database (...]
    Review Risankizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Benralizumab.[Drugs and Lactation Database (...]
    Review Benralizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Ravulizumab.[Drugs and Lactation Database (...]
    Review Ravulizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Ixekizumab.[Drugs and Lactation Database (...]
    Review Ixekizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Sutimlimab.[Drugs and Lactation Database (...]
    Review Sutimlimab.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...